Product Code: PM1128
The global Age-related Macular Degeneration (AMD) market size is expected to reach USD 14.43 billion by 2030 according to a new study by Polaris Market Research. The report "Age-related Macular Degeneration (AMD) Market Share, Size, Trends, Industry Analysis Report, By Drugs (Lucentis, Eylea, Avastin, Others); By Product; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The AMD industry is boosted by an increase in the frequency of eye-related diseases and an increase in the number of refractive eye surgeries for eye disorders. As per the WHO, in 2019, around 2.2 billion people from across the globe have been suffering from one or the other kind of visual impairment, and out of this, 123.7 million people have uncorrected refractive errors.
The different type of refractive errors includes nearsightedness (myopia), farsightedness (hyperopia), astigmatism, and presbyopia. Glasses, contact lenses, and laser eye surgery are the commonly available treatment for the correction of refractive errors. Due to the discomfort offered by wearing glasses and contact lenses, more and more people are inclined towards the adoption of refractive eye surgery to correct their refractive errors.
Furthermore, as per the American Refractive Surgery Council, in 2017, more than 29 million LASIK procedures were performed in the US. As per the American Association of Ophthalmology, in the US, 70% to 80% of people with refractive error opt for LASIK eye surgery, and 20% to 30% opt for PRK surgery. Intravitreal wearables segment accounted for the leading share in the market. The intravitreal segment is growing in popularity because tailored drug administration makes it more effective. In addition, the various anti-VEGF injections are given intravitreal or intraocularly. Anti-Vascular Endothelial Growth Factor medications are used to treat wet AMD (anti-VEGF).
Lucentis (ranibizumab) and Eylea (aflibercept) are two FDA-approved medications that are commonly prescribed for AMD. Avastin (bevacizumab), an off-label medication, is also widely utilized. Wet AMD is also treated with photodynamic therapy (PDT), which reduces the progression of vision impairment.
Industry players such as F. Hoffmann La Roche, Alimera Sciences Inc., ALLERGAN, Regeneron Pharmaceuticals, Bausch & Lomb Incorporated, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Acucela Inc., Ophthotech Corporation, Pfizer Inc, Rxi Pharmaceuticals Inc., Santen Pharmaceuticals Co., and Valeant Pharmaceuticals International, Inc. are some key players operating in the industry. In January 2021, Novartis started phase III trials of its candidate "brolucizumab" for the cure of AMD to assess its tolerability and effectiveness.
Polaris Market Research has segmented the Age-related Macular Degeneration (AMD) Market report based on product, drugs, route of administration, distribution channel, and region:
Age-related Macular Degeneration (AMD), Product Outlook (Revenue - USD Billion, 2018 - 2030)
Wet AMD
Dry AMD
Age-related Macular Degeneration (AMD), Drugs Outlook (Revenue - USD Billion, 2018 - 2030)
Lucentis
Eylea
Avastin
Others
Age-related Macular Degeneration (AMD), Route of Administration Outlook (Revenue - USD Billion, 2018 - 2030)
Intravenous
Intravitreal
Age-related Macular Degeneration (AMD), Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Age-related Macular Degeneration (AMD), Regional Outlook (Revenue - USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
France
Germany
UK
Italy
Spain
Netherlands
Russia
Asia Pacific
China
India
Japan
Malaysia
South Korea
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Age-related Macular Degeneration (AMD) Market Insights
- 4.1. Age-related Macular Degeneration (AMD) - Industry Snapshot
- 4.2. Age-related Macular Degeneration (AMD) Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing geriatric population
- 4.2.1.2. Rising demand from the US, European and Asian population
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High price for the medicines for AMD
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Age-related Macular Degeneration (AMD) Industry Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Age-related Macular Degeneration (AMD) Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 5.3. Wet AMD
- 5.3.1. Global Age-related Macular Degeneration (AMD) Market, by Wet AMD, by Region, 2018 - 2030 (USD Billion)
- 5.4. Dry AMD
- 5.4.1. Global Age-related Macular Degeneration (AMD) Market, by Dry AMD, by Region, 2018 - 2030 (USD Billion)
6. Global Age-related Macular Degeneration (AMD) Market, by Drugs
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 6.3. Lucentis
- 6.3.1. Global Age-related Macular Degeneration (AMD) Market, by Lucentis, by Region, 2018 - 2030 (USD Billion)
- 6.4. Eylea
- 6.4.1. Global Age-related Macular Degeneration (AMD) Market, by Eylea, by Region, 2018 - 2030 (USD Billion)
- 6.5. Avastin
- 6.5.1. Global Age-related Macular Degeneration (AMD) Market, by Avastin, by Region, 2018 - 2030 (USD Billion)
- 6.6. Others
- 6.6.1. Global Age-related Macular Degeneration (AMD) Market, by Others, by Region, 2018 - 2030 (USD Billion)
7. Global Age-related Macular Degeneration (AMD) Market, by Route of Administration
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 7.3. Intravenous
- 7.3.1. Global Age-related Macular Degeneration (AMD) Market, by Intravenous, by Region, 2018 - 2030 (USD Billion)
- 7.4. Intravitreal
- 7.4.1. Global Age-related Macular Degeneration (AMD) Market, by Intravitreal, by Region, 2018 - 2030 (USD Billion)
8. Global Age-related Macular Degeneration (AMD) Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 8.3. Hospital Pharmacies
- 8.3.1. Global Age-related Macular Degeneration (AMD) Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
- 8.4. Retail Pharmacies
- 8.4.1. Global Age-related Macular Degeneration (AMD) Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
- 8.5. Online Pharmacies
- 8.5.1. Global Age-related Macular Degeneration (AMD) Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)
9. Global Age-related Macular Degeneration (AMD) Market, by Geography
- 9.1. Key findings
- 9.2. Introduction
- 9.2.1. Age-related Macular Degeneration (AMD) Market Assessment, By Geography, 2018 - 2030 (USD Billion)
- 9.3. Age-related Macular Degeneration (AMD) Market - North America
- 9.3.1. North America: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.3.2. North America: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.3.3. North America: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.3.4. North America: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.3.5. Age-related Macular Degeneration (AMD) Market - U.S.
- 9.3.5.1. U.S.: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.3.5.2. U.S.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.3.5.3. U.S.: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.3.5.4. U.S.: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.3.6. Age-related Macular Degeneration (AMD) Market - Canada
- 9.3.6.1. Canada: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.3.6.2. Canada: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.3.6.3. Canada: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.3.6.4. Canada: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4. Age-related Macular Degeneration (AMD) Market - Europe
- 9.4.1. Europe: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.2. Europe: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.3. Europe: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.4. Europe: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4.5. Age-related Macular Degeneration (AMD) Market - UK
- 9.4.5.1. UK: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.5.2. UK: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.5.3. UK: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.5.4. UK: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4.6. Age-related Macular Degeneration (AMD) Market - France
- 9.4.6.1. France: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.6.2. France: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.6.3. France: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.6.4. France: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4.7. Age-related Macular Degeneration (AMD) Market - Germany
- 9.4.7.1. Germany: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.7.2. Germany: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.7.3. Germany: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.7.4. Germany: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4.8. Age-related Macular Degeneration (AMD) Market - Italy
- 9.4.8.1. Italy: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.8.2. Italy: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.8.3. Italy: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.8.4. Italy: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4.9. Age-related Macular Degeneration (AMD) Market - Spain
- 9.4.9.1. Spain: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.9.2. Spain: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.9.3. Spain: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.9.4. Spain: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4.10. Age-related Macular Degeneration (AMD) Market - Netherlands
- 9.4.10.1. Netherlands: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.10.2. Netherlands: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.10.3. Netherlands: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.10.4. Netherlands: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.4.11. Age-related Macular Degeneration (AMD) Market - Russia
- 9.4.11.1. Russia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.4.11.2. Russia.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.4.11.3. Russia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.4.11.4. Russia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.5. Age-related Macular Degeneration (AMD) Market - Asia Pacific
- 9.5.1. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.5.2. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.5.3. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.5.4. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.5.5. Age-related Macular Degeneration (AMD) Market - China
- 9.5.5.1. China: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.5.5.2. China.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.5.5.3. China: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.5.5.4. China: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.5.6. Age-related Macular Degeneration (AMD) Market - India
- 9.5.6.1. India: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.5.6.2. India.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.5.6.3. India: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.5.6.4. India: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.5.7. Age-related Macular Degeneration (AMD) Market - Japan
- 9.5.7.1. Japan: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.5.7.2. Japan.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.5.7.3. Japan: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.5.7.4. Japan: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.5.8. Age-related Macular Degeneration (AMD) Market - Malaysia
- 9.5.8.1. Malaysia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.5.8.2. Malaysia.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.5.8.3. Malaysia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.5.8.4. Malaysia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.5.9. Age-related Macular Degeneration (AMD) Market - Indonesia
- 9.5.9.1. Indonesia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.5.9.2. Indonesia.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.5.9.3. Indonesia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.5.9.4. Indonesia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.5.10. Age-related Macular Degeneration (AMD) Market - South Korea
- 9.5.10.1. South Korea: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.5.10.2. South Korea.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.5.10.3. South Korea: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.5.10.4. South Korea: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.6. Age-related Macular Degeneration (AMD) Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.6.2. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.6.3. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.6.4. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.6.5. Age-related Macular Degeneration (AMD) Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.6.5.2. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.6.5.3. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.6.5.4. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.6.6. Age-related Macular Degeneration (AMD) Market - South Africa
- 9.6.6.1. South Africa: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.6.6.2. South Africa: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.6.6.3. South Africa: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.6.6.4. South Africa: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.6.7. Age-related Macular Degeneration (AMD) Market - Israel
- 9.6.7.1. Israel: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.6.7.2. Israel: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.6.7.3. Israel: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.6.7.4. Israel: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.6.8. Age-related Macular Degeneration (AMD) Market - UAE
- 9.6.8.1. UAE: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.6.8.2. UAE: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.6.8.3. UAE: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.6.8.4. UAE: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.7. Age-related Macular Degeneration (AMD) Market - Latin America
- 9.7.1. Latin America: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.7.2. Latin America: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.7.3. Latin America: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.7.4. Latin America: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.7.5. Age-related Macular Degeneration (AMD) Market - Mexico
- 9.7.5.1. Mexico: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.7.5.2. Mexico: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.7.5.3. Mexico: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.7.5.4. Mexico: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.7.6. Age-related Macular Degeneration (AMD) Market - Brazil
- 9.7.6.1. Brazil: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.7.6.2. Brazil: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.7.6.3. Brazil: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.7.6.4. Brazil: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
- 9.7.7. Age-related Macular Degeneration (AMD) Market - Argentina
- 9.7.7.1. Argentina: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
- 9.7.7.2. Argentina: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
- 9.7.7.3. Argentina: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
- 9.7.7.4. Argentina: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Acucela Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Alimera Sciences Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. ALLERGAN
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Bausch & Lomb Incorporated
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Bayer AG
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. F. Hoffmann La Roche
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. GlaxoSmithKline PLC
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Novartis AG
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Ophthotech Corporation
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Pfizer Inc
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Regeneron Pharmaceuticals
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Rxi Pharmaceuticals Inc.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13. Santen Pharmaceuticals Co.
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
- 11.14. Valeant Pharmaceuticals International, Inc.
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development